# A Study of LY2875358 in Participants With Advanced Cancer

> **NCT01287546** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 117 (estimated)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** LY2875358
- **DRUG:** LY2875358 + erlotinib
- **DRUG:** LY2875358 at Part A highest dose
- **DRUG:** LY2875358 at Part A highest dose + trametinib

## Key facts

- **NCT ID:** NCT01287546
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-13
- **Primary completion:** 2015-01-08
- **Final completion:** 2016-10-26
- **Target enrollment:** 117 (ESTIMATED)
- **Last updated:** 2017-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01287546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01287546, "A Study of LY2875358 in Participants With Advanced Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01287546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*